et al. FDA approval summary: pembrolizumab for recurrent locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma expressing PD-L1. Oncologist 24, 103–109 (2019). Article CAS PubMed Google Scholar Shitara, K. et al. Pembrolizumab versus paclitaxel for previously treated, ...
US Food and Drug Administration. Summary of safety and effectiveness data (SSED) for VENTANA PD-L1 (SP142) assay.FDAhttp://www.accessdata.fda.gov/cdrh_docs/pdf16/p160006b.pdf(2016). US Food and Drug Administration. Durvalumab (Imfinzi).FDAhttps://www.fda.gov/drugs/resources-information-a...
number of PD-L1-positive exosomes and the level of PD-L1 expression in the tumor tissue, although tumor-specific exosomes could not be distinguished in the present study. However, Chen et al. (2018) recently proposed that exosomal PD-L1 is associated with an anti-PD-1 response in melanoma,...
ArticleCASGoogle Scholar Narayan P, Wahby S, Gao JJ et al (2020) FDA approval summary: Atezolizumab plus paclitaxel protein-bound for the treatment of patients with advanced or metastatic TNBC whose tumors express PD-L1. Clin Cancer Res 26:2284–2289 ArticleCASGoogle Scholar Naruse T, Yanamoto...
[]Summary: 1. Regardless of whether it's the QC or PD protocol, as long as it supports the 12V3A level, it can achieve a full load output of 5V5.5A or more. Supporting the 12V2.5A level can achieve an output of 5V5A or more. ...
Summary XopD, a type III secretion effector from Xanthomonas euvesicatoria (Xcv), the causal agent of bacterial spot of tomato, is required for pathogen growth and delay of host symptom development. XopD carries a C-terminal SUMO protease domain, a host range determining nonspecific DNA-binding...
Neurological Complications Associated With Anti-Programmed Death 1 (PD-1) Antibodies (vol 74, pg 1216, 2017) C J.,Liao,Markovic,... 被引量: 0发表: 0年 Neurological Complications Associated With Anti–Programmed Death 1 (PD-1) Antibodies Importance: Neurological complications are an increasingly...
Mol. Cell 81, 1216–1230 (2021). Article CAS PubMed Google Scholar Wan, L. et al. Impaired cell fate through gain-of-function mutations in a chromatin reader. Nature 577, 121–126 (2020). Article CAS PubMed Google Scholar Shi, B. et al. UTX condensation underlies its tumour-...
C-Jun, a critical component of AP-1, exerts essential functions in various tumors, including melanoma, and is believed to be a druggable target for cancer therapy. Unfortunately, no effective c-Jun inhibitors are currently approved for clinical use. The
Data distribution was assumed to be normal, but this was not formally tested. Reporting summary Further information on research design is available in the Nature Portfolio Reporting Summary linked to this article.Data availability RNA-sequencing data that support the findings of this study have been ...